Apellis Pharmaceuticals (APLS) CEO awarded 195,952 RSUs and details trust-held shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Apellis Pharmaceuticals CEO Cedric Francois reported a new equity grant of 195,952 shares of common stock on January 28, 2026, awarded as restricted stock units at $0 per share. Following this grant, he directly holds 481,997 Apellis common shares.
The RSU award vests 25% each year over four years from the grant date, subject to continued service. Additional Apellis shares are held by several trusts, including The Cedric Francois Irrevocable Trust of 2023 - 2, The Cedric Francois Irrevocable Trust of 2023, The Francois Grossi Trust, and The Francois-DuBois Educational Trust, where Francois disclaims beneficial ownership except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Francois Cedric
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 195,952 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 481,997 shares (Direct);
Common Stock — 307,946 shares (Indirect, Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2))
Footnotes (1)
- This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service. The securities are held by The Cedric Francois Irrevocable Trust of 2023 - 2. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023 - 2. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 - 2 except to the extent of his pecuniary interest therein. The securities are held by The Cedric Francois Irrevocable Trust of 2023. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein. The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein. The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.
FAQ
What insider transaction did Apellis (APLS) CEO Cedric Francois report on this Form 4?
Cedric Francois reported a grant of 195,952 shares of Apellis common stock on January 28, 2026. The shares were issued as a restricted stock unit award at $0 per share, increasing his directly held Apellis stake to 481,997 common shares after the transaction.
How do the restricted stock units granted to Apellis (APLS) CEO Cedric Francois vest?
The restricted stock unit award granted on January 28, 2026 vests 25% annually over four years. Vesting is conditioned on continued service, meaning Francois must remain in service with Apellis each year for a portion of the 195,952 RSUs to become fully earned.
What is Cedric Francois’s direct Apellis (APLS) common stock ownership after this Form 4 transaction?
After the reported grant, Cedric Francois directly holds 481,997 shares of Apellis common stock. This figure represents his direct ownership only and does not add in any Apellis shares that are held through various related trusts disclosed as indirect holdings in the filing.